CA3087761A1 - Molecules proteiques et utilisations associees - Google Patents

Molecules proteiques et utilisations associees Download PDF

Info

Publication number
CA3087761A1
CA3087761A1 CA3087761A CA3087761A CA3087761A1 CA 3087761 A1 CA3087761 A1 CA 3087761A1 CA 3087761 A CA3087761 A CA 3087761A CA 3087761 A CA3087761 A CA 3087761A CA 3087761 A1 CA3087761 A1 CA 3087761A1
Authority
CA
Canada
Prior art keywords
amino acid
proteinaceous molecule
cell
acid residues
modified forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3087761A
Other languages
English (en)
Inventor
Sudha RAO
Peter MILBURN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epiaxis Therapeutics Pty Ltd
Original Assignee
Epiaxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900108A external-priority patent/AU2018900108A0/en
Application filed by Epiaxis Therapeutics Pty Ltd filed Critical Epiaxis Therapeutics Pty Ltd
Publication of CA3087761A1 publication Critical patent/CA3087761A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules protéiques correspondant à un site d'acétylation et leur utilisation pour inhiber ou réduire la localisation nucléaire d'un polypeptide localisable nucléaire, tel que PD-1, PD-L1 et PD-L2. La présente invention concerne également l'utilisation des molécules protéiques pour modifier au moins l'une parmi (i) formation ; (ii) prolifération ; (iii) maintenance ; (iv) transition de cellules épithéliales en mésenchymateuses (EMT) ; ou (v) transition de cellules mésenchymateuses en épithéliales (MET) d'une cellule surexprimant PD-1-, PD-L1- ou PD-L2, et pour traiter ou prévenir un cancer chez un sujet.
CA3087761A 2018-01-15 2019-01-15 Molecules proteiques et utilisations associees Pending CA3087761A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018900108A AU2018900108A0 (en) 2018-01-15 Proteinaceous molecules and uses therefor
AU2018900108 2018-01-15
PCT/AU2019/050024 WO2019136531A1 (fr) 2018-01-15 2019-01-15 Molécules protéiques et utilisations associées

Publications (1)

Publication Number Publication Date
CA3087761A1 true CA3087761A1 (fr) 2019-07-18

Family

ID=67218182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3087761A Pending CA3087761A1 (fr) 2018-01-15 2019-01-15 Molecules proteiques et utilisations associees

Country Status (8)

Country Link
US (1) US20200339691A1 (fr)
EP (1) EP3740496A4 (fr)
JP (1) JP2021510538A (fr)
CN (1) CN111936509A (fr)
AU (1) AU2019207534B2 (fr)
CA (1) CA3087761A1 (fr)
SG (1) SG11202006459XA (fr)
WO (1) WO2019136531A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210055302A1 (en) * 2018-01-15 2021-02-25 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
AU2020340466A1 (en) * 2019-09-03 2022-03-24 The Council Of The Queensland Institute Of Medical Research Methods and agents for determining patient status
CN111411082B (zh) * 2020-03-26 2022-04-01 中山大学孙逸仙纪念医院 一种培养CD90posi细胞的培养基及其培养方法
KR20230146025A (ko) * 2021-01-19 2023-10-18 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 신규 바이사이클릭 펩티드
CN112759626B (zh) * 2021-02-03 2022-10-14 安徽大学 一种核定位信号肽及其序列和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002328203C1 (en) * 2001-08-24 2009-01-08 Migenix Inc. Antimicrobial and anti-inflammatory peptides
WO2008021542A2 (fr) * 2006-08-17 2008-02-21 Cell Signaling Technology, Inc. Sites d'acétylation de la lysine
US20130017199A1 (en) * 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
EP3290517B1 (fr) * 2015-04-30 2020-01-01 Kyoto University Procédé pour prévoir l'effet thérapeutique d'un inhibiteur de pd-1/pd-l1 en utilisant une anomalie dans pd-l1(cd274) comme indice
WO2017220602A1 (fr) * 2016-06-21 2017-12-28 Herlev Hospital Peptides pdl1 utilisés dans des vaccins contre le cancer

Also Published As

Publication number Publication date
JP2021510538A (ja) 2021-04-30
US20200339691A1 (en) 2020-10-29
CN111936509A (zh) 2020-11-13
AU2019207534B2 (en) 2022-06-09
EP3740496A4 (fr) 2021-12-08
EP3740496A1 (fr) 2020-11-25
WO2019136531A1 (fr) 2019-07-18
AU2019207534A1 (en) 2020-07-23
SG11202006459XA (en) 2020-08-28

Similar Documents

Publication Publication Date Title
AU2019207534B2 (en) Proteinaceous molecules and uses therefor
AU2006291541B2 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP5490343B2 (ja) Ｊｎｋシグナル導入経路の細胞透過性ペプチドインヒビター
KR102373603B1 (ko) 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
CA3023670A1 (fr) Agents agonistes de cd47 induisant la mort cellulaire programmee et leur utilisation dans le traitement de maladies associees a des defauts dans la mort cellulaire programmee
ES2439950T3 (es) Péptidos con permeabilidad celular inhibidores de la ruta de transducción de señales de la JNK
CN102741269A (zh) Gadd45β靶向剂
WO2011044374A1 (fr) Agents thérapeutiques de peptide capcna pour le cancer
CA3080617A1 (fr) Conjugues polypeptidiques pour l'administration intracellulaire de peptides agrafes
EP2751291B1 (fr) Procédés de préparation de peptidomimétiques à haut débit, médicaments biodisponibles oralement et compositions les contenant
CA2906775A1 (fr) Peptides bh4 stabilises et leurs utilisations
AU2017214761B2 (en) Proteinaceous compounds and uses therefor
CN106659764B (zh) 环状鞘脂激活蛋白原肽及其用途
KR102315997B1 (ko) Baf57 재조합 융합 단백질 및 이의 용도
KR101323669B1 (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
CA3208598A1 (fr) Nouveaux peptides bicycliques
EP4444740A2 (fr) Macrocycles peptidomimétiques p53
AU2012203529A1 (en) Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213